These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23816949)

  • 1. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
    Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC
    J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.
    Coplan PM; Kale H; Sandstrom L; Landau C; Chilcoat HD
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1274-82. PubMed ID: 24123484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
    Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
    Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
    Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
    Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
    Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
    Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the abuse of tapentadol immediate release: the first 24 months.
    Dart RC; Cicero TJ; Surratt HL; Rosenblum A; Bartelson BB; Adams EH
    J Opioid Manag; 2012; 8(6):395-402. PubMed ID: 23264317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
    Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
    Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.
    Rossiter LF; Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Michna E
    J Med Econ; 2014 Apr; 17(4):279-87. PubMed ID: 24559196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.
    Sessler NE; Downing JM; Kale H; Chilcoat HD; Baumgartner TF; Coplan PM
    Pharmacoepidemiol Drug Saf; 2014 Dec; 23(12):1238-46. PubMed ID: 24916486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
    McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
    J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of FDA approval of a generic competitor to OxyContin (oxycodone HCl controlled-release) tablets on the abuse of oxycodone.
    Bailey JE; Barton PL; Lezotte D; Lowenstein SR; Dart RC
    Drug Alcohol Depend; 2006 Sep; 84(2):182-7. PubMed ID: 16510252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
    Sellers EM; Perrino PJ; Colucci SV; Harris SC
    J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS(®)) System.
    Zosel A; Bartelson BB; Bailey E; Lowenstein S; Dart R
    J Am Acad Child Adolesc Psychiatry; 2013 Feb; 52(2):196-204.e2. PubMed ID: 23357446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER.
    Geoffrey Severtson S; Kreider SED; Amioka EC; Margolin ZR; Iwanicki JL; Dart RC
    Pain Med; 2020 Dec; 21(12):3660-3668. PubMed ID: 33094329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
    Butler SF; Cassidy TA; Chilcoat H; Black RA; Landau C; Budman SH; Coplan PM
    J Pain; 2013 Apr; 14(4):351-8. PubMed ID: 23127293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits.
    Davis JM; Severtson SG; Bucher-Bartelson B; Dart RC
    Pharmacoepidemiol Drug Saf; 2014 Jan; 23(1):18-25. PubMed ID: 24130046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
    Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
    Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation.
    Peacock A; Degenhardt L; Hordern A; Larance B; Cama E; White N; Kihas I; Bruno R
    Int J Drug Policy; 2015 Dec; 26(12):1265-72. PubMed ID: 26123898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison.
    Hughes AA; Bogdan GM; Dart RC
    Clin Toxicol (Phila); 2007; 45(2):144-51. PubMed ID: 17364631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.